Follow us on Twitter
twitter icon@FreshPatents


Polypeptide patents

      

This page is updated frequently with new Polypeptide-related patent applications.




 Bardcoded protein array for multiplex single-molecule interaction profiling patent thumbnailnew patent Bardcoded protein array for multiplex single-molecule interaction profiling
Methods for attaching barcodes to polypeptides are provided. Methods for detecting molecular interactions at the single molecule level are provided.
President And Fellows Of Harvard College


 Rhamnose promoter expression system patent thumbnailnew patent Rhamnose promoter expression system
The prokaryotic signal sequence is selected from signal peptides of periplasmatic binding proteins for sugars, amino acids, vitamins and ions. The expression of the nucleic acid sequence is controlled by the promoter region.

 Type ii restriction modification system methylation subunit of alicyclobacillus acidocaldarius patent thumbnailnew patent Type ii restriction modification system methylation subunit of alicyclobacillus acidocaldarius
Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for modulating or altering recombination inside or outside of a cell using isolated and/or purified polypeptides and/or nucleic acid sequences from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc


 Novel methods, polypeptides and uses thereof patent thumbnailnew patent Novel methods, polypeptides and uses thereof
The present invention provides methods for the production of recombinant polypeptides having serine protease activity, polypeptides obtainable by such methods and use of said polypeptides in medicine, cosmetics and industry. In particular, the invention provides recombinantly expressed mutants of trypsin i from atlantic cod, which mutants exhibit improved stability and/or catalytic properties relative to the wildtype trypsin purified from cod..
Enzymatica Ab


 Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease patent thumbnailnew patent Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore


 Detergent composition patent thumbnailnew patent Detergent composition
The present invention concerns a detergent and a pharmaceutical composition comprising a deoxyribonuclease (dnase), wherein the dnase is obtained from a fungal source. It further concerns a laundering method and the use of dnase.
Novozymes A/s


 Stabilized single domain antibodies patent thumbnailnew patent Stabilized single domain antibodies
The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising vhhs in biological circulatory systems..
Ablynx N.v.


 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics patent thumbnailnew patent Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against krtcap3, fam26f, mgc52498, fam70a or tmem154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages.
Compugen Ltd


 Antibodies to hgf and compositions containing patent thumbnailnew patent Antibodies to hgf and compositions containing
The present invention is directed to antibodies and fragments thereof having binding specificity for hgf. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the vh, vl and cdr polypeptides described herein, and the polynucleotides encoding them.
Alderbio Holdings Llc


 Fgfr fusions patent thumbnailnew patent Fgfr fusions
Fusion polypeptides have an fgfr2 polypeptide and cdnas encode such fusion polypeptides. Methods of diagnosing the presence of the fusion polypeptides or of a gene or rna sequence coding therefore in a sample from a subject as well as methods of treatment of a tumor instructed by the latter diagnosis..
Debiopharm International Sa


new patent

Constructs having a sirp-alpha domain or variant thereof

The present disclosure features signal-regulatory protein α (sirp-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory t-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The sirp-α constructs include a high affinity sirp-α d1 domain or variant thereof that binds cd47 with higher affinity than a wild-type sirp-α.
Alexo Therapeutics Inc.

new patent

Sperm-specific cation channel, and uses therefor

Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (catsper1) are disclosed. The catsper1 protein is shown to be specifically expressed in sperm and to be necessary for sperm motility.
Children's Medical Center Corporation

new patent

Peptide agonists of glp-1 activity

Novel peptide agonists of glp-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the glp-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable.
Zealand Pharma A/s

new patent

Novel specific-binding polypeptides and uses thereof

The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of swiss prot q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of swiss prot q9npf7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of swiss prot q16552 and swiss prot q9npf7.
Pieris Pharmaceuticals Gmbh

new patent

Met e 1 tropomyosin variants for use in allergen-specific immunotherapy

The present invention provides isolated met e 1 polypeptides and nucleic acids encoding the isolated polypeptides that can prevent and/or alleviate an allergic response to shellfish tropomyosin. The polypeptides are based on the shrimp tropomyosin met e 1 protein and have been modified to act as hypoallergens.
The Regents Of The University Of California

new patent

Mutant fragments of ospa and methods and uses relating thereto

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein a (ospa), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a borrelia infection and a method of immunizing a subject.. .
Valneva Austria Gmbh

new patent

Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Described herein is the generation of optimized h5n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

new patent

Apelin polypeptides

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed..
Amgen Inc.

new patent

Novel ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof

The present invention relates to novel ruthenium complexes and related borohydride complexes, and their use for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including preparing polyamides (e.g., polypeptides) by reacting dialcohols and diamines or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones), cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to novel uses of certain pyridine ruthenium complexes..
Yeda Research And Development Co. Ltd.

new patent

Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase

Herein is reported a method for producing a polypeptide in monomeric form comprising the following step: recovering the polypeptide in monomeric form from an ion exchange chromatography material by applying a solution comprising a non-ionic polymer and an additive.. .
Hoffmann-la Roche Inc.

new patent

Site specific protein modifications

The present invention relates to method and reagents for use in site-selective modification of protein and peptide. The site selective modification is a selective derivation of the amino functionality at the n-terminus of the protein or the polypeptide using the presence of a neighboring histidine amino acid to increase the reactivity of the n-terminal amino functionality.
Novartis Ag

new patent

Homogenous antibody drug conjugates via enzymatic methods

The present application in one aspect provide fc-containing polypeptide conjugates comprising an fc-containing polypeptide conjugated to a conjugate moiety, wherein the fc-containing polypeptide comprises an n-glycosylated fc region comprising an acceptor glutamine residue flanked by an n-glycosylation site and wherein the conjugate moiety is conjugated to the fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases.
Cspc Dophen Corporation

new patent

Delivery of therapeutic agents by a collagen binding protein

Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a pth/pthrp receptor agonist are provided.
Montefiore Medical Center

new patent

Cancer treatments

This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., abraxane®/anti-vegf polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided..
Mayo Foundation For Medical Education And Research

new patent

Transmission blocking vaccines for mosquito-borne flaviviruses

Disclosed are transmission blocking vaccines for prevention or spread of one or more flaviviruses, and in particular, for prevention or spread of dengue virus. Vaccines can incorporate a polypeptide or a recombinant virus encoding a polypeptide that is non-homologous to human proteins and that is involved in flavivirus infection in a mosquito.
University Of South Carolina

new patent

Haemophilus influenzae type iv pili

The invention described herein relates to a haemophilus influenzae (h. Influenzae) regulon encoding type iv pili.
Nationwide Children's Hospital, Inc.

new patent

Biomarker directed multi-target immunotherapy

This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted listeria-based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a.
Advaxis, Inc.

new patent

Pap peptide analogues

The application provides a polypeptide comprising the sequence slmtnlaal, ser 13 to leu 21 of amino acid sequence shown in fig. 1 or seq id no 1, and having hla-a2 haplotype binding activity, or a polynucleotide encoding said polypeptide.
The Nottingham Trent University

new patent

Pharmaceutical composition against chronic bacterial infections

The present invention relates to a polypeptide comprising a peptidoglycan hydrolase for use as a medicament for the treatment of chronic bacterial infections. The present invention further relates to a polypeptide comprising a peptidoglycan hydrolase comprising an endopeptidase, n-acetyl-muramoyl-l-alanine-amidase, n-acetyl-muramidase, n-acetyl-glucosaminidase and/or lytic transglycosylase..
Lysando Ag

new patent

Thermostabilization of proteins

Provided are compositions comprising a cocaine esterase (coce) and a compound that thermostabilizes the coce. Also provided are methods of thermostabilizing a cocaine esterase.
The Regents Of The University Of Michigan

new patent

Methods and compositions for treating phenylketonuria

The present invention provides compositions and methods of treating hyperphenylalaninemia (e.g., phenylketonuria) in a subject in need thereof comprising administering to the subject an effective amount of a phenylalanine dehydrogenase (phedh) polypeptide. The present invention also provides pharmaceutical formulations comprising phedh for lowering the phenylalanine concentration in the subject (e.g., in the intestines and/or blood)..
Children's National Medical Center

new patent

Pharmaceutical composition containing indometacin and/or acemetacin

The invention relates to a pharmaceutically active composition or pharmaceutical form of administering that contains at least one of the active ingredients indomethacin or acemetacin and optionally other adjuvants, the composition containing the active ingredient, or a mixture of the active ingredients, in micronized form, preferably mixed with at least one flavonoid derivative or a polypeptide or with a mixture of such compounds. .

Methods and compositions for expression of polypeptides in a cell

Disclosed herein are vector systems for expression of polypeptides in eukaryotic cells; and methods of obtaining high-level expression of polypeptides in a eukaryotic cell. Methods and compositions for obtaining stable, long-term expression of recombinant polypeptides are also provided.
Celltheon Corporation

Enzymatic synthesis of optically active chiral amines

The present invention relates to a method of enantioselective enzymatic transamination of (1r)-1-hydroxy-1-phenylacetone (r-pac) to a chiral amine 1r, 2s-norephedrine in the presence of an isopropylamine catalyzed by enantioselective transaminase. Isopropylamine is converted to acetone in the process.
Embio Limited

Activity of fe-s cluster requiring proteins

The present invention is related to a recombinant host cell, in particular a yeast cell, comprising a dihydroxy-acid dehydratase polypeptide. The invention is also related to a recombinant host cell having increased specific activity of the dihydroxy-acid dehydratase polypeptide as a result of increased expression of the polypeptide, modulation of the fe—s cluster biosynthesis of the cell, or a combination thereof.
Butamax Advanced Biofuels Llc

Polynucleotides and polypeptides in plants

The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
Mendel Biotechnology, Inc.

Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same

The present invention provides protease-cleavage resistant molecules comprising shiga toxin effector polypeptides capable of exhibiting potent, shiga toxin functions (e.g. Subcellular routing and cytotoxicity).
Molecular Templates, Inc.

Methods for reprogramming cells and uses thereof

A method of obtaining a cardiac multipotent or unipotent cell, comprising: i) providing a cell of a first type which is not a cardiac multipotent or unipotent cell; ii) introducing into the cell of a first type an agent capable of remodeling the chromatin and/or dna of the cell, wherein the agent capable of remodeling the chromatin and/or dna is a histone acetylator, an inhibitor of histone deacetylation, a dna demethylator, and/or a chemical inhibitor of dna methylation; iii) introducing into the cell of a first type a reprogramming polypeptide and/or a polynucleotide encoding said reprogramming polypeptide, wherein the reprogramming polypeptide comprises mesp1, brachyury (t), nkx2.5, and/or tbx5; and iv) placing or maintaining the cell in a cardiac cell culture medium and maintaining intracellular levels of the reprogramming polypeptide or the polynucleotide encoding the reprogramming polypeptide for a sufficient period of time to allow a cardiac multipotent or unipotent cell to be obtained.. .
Genesis Technologies Limited

Methods for reprogramming cells and uses thereof

An in vitro human neural multipotent, unipotent, or somatic cell possessing all of the following characteristics: is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; is not differentiated from a pluripotent cell; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a neural stem cell, neural precursor cell, neural progenitor cell, neuroblast, or neuron; is not a cancerous cell; is stable and not artificially maintained by forced gene expression and may be maintained in standard neural stem cell media or neural media; and does not exhibit uncontrolled growth, teratoma formation, and tumor formation in vivo; wherein the cell comprises at least one polypeptide or an expression vector encoding at least one polypeptide selected from the group consisting of: musashi1 (msi1); ngn2; msi1 and ngn2; msi1 and methyl-cpg binding domain protein 2 (mbd2); ngn2 and mbd2; msi1, ngn2 and mbd2; achaete-scute homolog 1 (ascl1); msi1, ngn2 and ascl1; msi1, ngn2, mbd2 and ascl1; sox2; msi1, ngn2 and sox2; and msi1, ngn2, mbd2 and sox2; wherein the expression vector is transiently expressed.. .
Genesis Technologies Limited

Genetic products differentially expressed in tumors and use thereof

The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in aberrant manner.
Ganymed Pharmaceuticals Ag

Chemokine receptor binding polypeptides

The present invention relates to polypeptides directed against or specifically binding to chemokine receptor cxcr2 and in particular to polypeptides capable of modulating signal transduction from cxcr2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of cxcr2..
Novartis Ag

Fusion proteins of collagen-binding domain and parathyroid hormone

Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (pth) and parathyroid hormone related peptide (pthrp) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy.
The Board Of Trustees Of The University Of Arkansas

Non-standard insulin analogues

An insulin analogue comprises a b-chain polypeptide containing a cyclohexanylalanine substitution at position b24 and optionally containing additional amino-acid substitutions at positions a8, b28, and/or b29. A proinsulin analogue or single-chain insulin analogue containing a b domain containing a cyclohexanylalanine substitution at position b24 and optionally containing additional amino-acid substitutions at positions a8, b28, and/or b29.
Case Western Reserve University

Toxin genes and methods for their use

Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided.
Athenix Corporation

Mutant fragments of ospa and methods and uses relating thereto

The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein a (ospa), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a borrelia infection and a method of immunizing a subject.. .
Valneva Austria Gmbh

Peptide ligands for hepatic stellate cells

Methods and compositions for identifying and using polypeptides that target hepatic stellate cells are described. Embodiments include a targeting composition that may include one or more polypeptides including an amino acid sequence that binds to an insulin-like growth factor 2 receptor.

Polyethylene glycol-modified integrin blocker hm-3 and use thereof

The present invention involves the pharmaceutical field, including integrin antagonists, which have the capacities of inhibiting angiogenesis of tumors, binding integrin. These antagonists are a kind of polypeptide, which was modified by polyethylene glycol and after modification, it can be used to treat tumors.
Hanmei Xu

Compositions and methods comprising klk3 or folh1 antigen

The present invention provides klk3 peptides, folh1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.. .
Advaxis, Inc.

Hybrid suppressor trna for vertebrate cells

This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal trna's, orthogonal aminoacyl-trna synthetases, orthogonal pairs of trna's/synthetases and unnatural amino acids.
Ambrx, Inc.

Methods and compositions for enhanced production of fatty aldehydes and fatty alcohols

The invention relates to the use of entd polypeptides, polynucleotides encoding the same, and homologues thereof to enhance the production of fatty aldehydes and fatty alcohols in a host cell.. .
Reg Life Sciences, Llc

Xylanase variants and polynucleotides encoding same

The present invention relates to xylanase variants, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of seq id no: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of seq id no: 3; and i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of seq id no: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants..
Novozymes A/s

Coagulation factor vii polypeptides

The present invention relates to modified coagulation factor vii polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment..
Novo Nordisk Healthcare Ag

Polypeptide having protease activity and methods for increasing its activity thereof

The present invention relates to a polypeptide having protease activity comprising a zinc finger protease domain, a helix-turn-helix domain and a gaf domain. The core protein sequence of the protease is shown as seq id no: 1.
Zhejiang University

Method for reducing viscosity in saccharification process

The present invention relates to compositions that can be used in hydrolyzing biomass such as compositions comprising a polypeptide having glycosyl hydrolase family 61/endoglucanase activity, methods for hydrolyzing biomass material, and methods for reducing viscosity of biomass mixture using a composition comprising a polypeptide having glycosyl hydrolase family 61/endoglucanase activity.. .
Danisco Us Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Polypeptides having phospholipase c activity and polynucleotides encoding same

The present invention provides polypeptides having phospholipase c activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing the polypeptides.
Novozymes A/s

Polypeptides having phospholipase c activity and polynucleotides encoding same

The present invention relates to a method of reducing the phospholipid content in an oil or fat composition and polypeptides having pi-specific phospholipase c activity as well as polypeptides having pc, pe-specific phospholipase c activity and combinations thereof capable of catalyzing this reduction. The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Novozymes A/s

Polypeptide structural motifs associated with cell signaling activity

Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three β-sheets and two α-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing..
Atyr Pharma, Inc.

Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders

The present invention relates to amino acid sequences that are directed against rank-l, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes..
Ablynx N.v.

Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to tumor necrosis factor-alpha. It further relates to single domain antibodies that are camelidae vhhs.
Ablynx N.v.

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Modified fgf-21 polypeptides and their uses

Modified fgf-21 polypeptides and uses thereof are provided.. .
Ambrx, Inc.

Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses

The invention relates to a chimeric protein comprising or consisting of, from n-terminal to c-terminal, (a) a n-terminal part of a bordetella cyaa protein (b) a heterologous polypeptide, and (c) a c-terminal part of a bordetella cyaa protein. The invention also relates to a polynucleotide encoding a deleted version of a bordetella cyaa, as well as a polynucleotide encoding this chimeric protein.
Genticel

Dipeptide comprising a non-proteogenic amino acid

Described is a dipeptide comprising a non-proteogenic amino acid, methods of making such and methods of using said dipeptide in a process of making a polypeptide or protein comprising one or more non-proteogenic amino acids.. .
Novo Nordisk A/s





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Polypeptide for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Polypeptide with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3943

file did exist - 3099

0 - 1 - 66